Ignyta Announces Entrectinib Clinical Case Report Presentation At The 2015 World Conference On Lung Cancer

SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that an abstract relating to entrectinib, the company’s proprietary oral tyrosine kinase inhibitor targeting solid tumors that harbor activating alterations to TrkA, TrkB, TrkC, ROS1 or ALK, has been selected for a mini-oral presentation at the 16th World Conference on Lung Cancer on September 9, 2015 in Denver, Colorado.

Help employers find you! Check out all the jobs and post your resume.

Back to news